Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial
Why the trial?
Patients with atrial fibrillation undergoing PCI for acute coronary syndrome need anticoagulation plus antiplatelet therapy, a combination that trades ischaemic protection against serious bleeding. The optimal early regimen — including escalated single platelet inhibition for one month alongside a NOAC — remained undefined.
Does a 1-month regimen of DOAC plus potent P2Y12 inhibitor reduce recurrent ischemic events and improve safety compared to DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome?
Population
602 patients with AF + ACS undergoing PCI (stopped early; 1,474 planned)
Comparison
DOAC + potent P2Y12 (prasugrel/ticagrelor) vs DOAC + clopidogrel + in-hospital ASA
Design
Open-label multicenter randomized trial; win-loss ratio analyses; stopped by DSMB
Follow-up
Primary endpoints at 6 weeks
Key result
In patients with atrial fibrillation and acute coronary syndrome, a 1-month regimen of a DOAC plus a potent P2Y12 inhibitor did not reduce ischemic events (WLR 1.19) but increased bleeding.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Where experts stand
Experts read EPIDAURUS as a clear safety signal against combining potent P2Y12 inhibitors with DOACs in AF patients after ACS, reinforcing clopidogrel as the standard choice in this setting.
EPIDAURUS tested whether swapping clopidogrel for a potent P2Y12 inhibitor (prasugrel or ticagrelor) alongside a DOAC could reduce ischemic events in patients with atrial fibrillation undergoing PCI for acute coronary syndrome. The trial was stopped early for safety after enrolling 602 patients, with more bleeding and no ischemic benefit in the intensified antiplatelet arm. Experts uniformly view the result as confirmatory rather than surprising, reinforcing that clopidogrel remains the right P2Y12 inhibitor for this population. The open question is whether the field should now test a different strategy altogether, such as temporarily pausing the DOAC around the acute event.
Agreement
Multiple experts agree that EPIDAURUS rules out routine use of potent P2Y12 inhibitors plus DOACs in AF patients with ACS, and that clopidogrel should remain the standard P2Y12 inhibitor in this setting.
4 clinicians say this directly
3 takes classified by contention axis so far — the map appears as more land.
Still unclear
Davide Capodanno raised whether the field is asking the wrong question and flagged that temporarily stopping the DOAC during the acute phase is being tested next. It remains unknown whether a DOAC-pause strategy could preserve ischemic protection while avoiding the bleeding excess seen here. How these findings will be incorporated into updated AF-ACS management guidelines is also unresolved.
Key expert perspectives
The result is unsurprising, but maybe we are asking the wrong question entirely
Capodanno noted that the safety stop for excess bleeding with ticagrelor and prasugrel was predictable. He questioned whether the field should reframe its approach, pointing to upcoming trials testing temporary DOAC interruption rather than intensified antiplatelet therapy in AF patients undergoing PCI.
Distilled from their postX post
Clopidogrel is the appropriate P2Y12 inhibitor for the majority of these patients
Granger stated plainly that clopidogrel remains the right P2Y12 inhibitor choice for most patients in this clinical scenario.
Distilled from their postOriginal post
Konstantinos RizasInterventional cardiologist, Ludwig Maximilians University MunichResults readoutAug 30First trial of its kind answers an important question against potent P2Y12 inhibitors plus DOACs
Rizas, a lead investigator, stated that EPIDAURUS answered a key clinical question and that the findings do not support routine use of potent P2Y12 inhibitors combined with direct oral anticoagulants in patients with AF and MI.
Distilled from their postOriginal post
Overview
Avoid potent P2Y12 inhibitors with DOAC after PCI in AF; challenges assumptions favoring early intensified antiplatelet therapy.
Key Points
- Assess the efficacy and safety of a 1-month dual antithrombotic regimen combining direct oral anticoagulants with potent P2Y12 inhibitors versus clopidogrel in patients with atrial fibrillation and acute coronary syndrome.
- Open-label, randomized controlled trial (EPIDAURUS, NCT04981041) comparing DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) against DOAC plus clopidogrel and in-hospital aspirin.
- Enrolled N=602 patients (154 female) of a planned 1,474 before premature study termination due to safety concerns raised by the Data and Safety Monitoring Board.
- Evaluated primary efficacy (recurrent ischemic events) and safety endpoints (death, major bleeding) 6 weeks post-randomization using win-loss ratio analyses.
- The trial was terminated prematurely after enrolling 602 patients due to safety concerns.
- Exploratory analyses showed potent P2Y12 inhibitors significantly increased Bleeding Academic Research Consortium (BARC) type ≥2 and ≥3 bleeding.
- Potent P2Y12 inhibitors demonstrated no clear reduction in recurrent ischemic complications compared to clopidogrel and in-hospital aspirin.
Evidence details
What drove the result?
| Outcome | Potent P2Y12 | Clopidogrel |
|---|---|---|
| Hierarchical composite: death, stent thrombosis, MI, ischemic stroke, systemic embolism, urgent revascularization | ||
| Win-loss ratio 1.19 (95% CI 0.61-2.32; p=0.610) · no clear ischemic benefit; per-arm counts not reported |
Limitations & tradeoffs
Safety
BARC type >=2 and >=3 bleeding were higher with the potent P2Y12 inhibitor (secondary endpoints; per-arm counts not reported).
Statistical certainty
premature termination (stopped by the DSMB for safety) at 602 of 1,474 planned patients leaves the trial underpowered.
Subgroup caution
the hierarchical win-loss design makes all subsequent analyses, including bleeding, exploratory.
Representation
only 18% of screened patients met inclusion criteria and agreed to participate.
Design limitations
the statistical design was modified during the course of the trial.
Structured PICO
Does a 1-month regimen of DOAC plus potent P2Y12 inhibitor reduce recurrent ischemic events and improve safety compared to DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome?
P
Population
602 patients (median age 78, 25.6% female) with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention, followed for 6 months.
I
Intervention
1-month regimen of DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor)
C
Comparator
DOAC plus clopidogrel and in-hospital aspirin
O
Outcome
Efficacy endpoint (recurrent ischemic events) and safety endpoints (including death and major bleeding), evaluated 6 weeks after randomization using separate win-loss ratio analysescomposite
Main Result
Effect estimate: WLR 1.19 (95% CI 0.61-2.32)
p-value: p=0.610
In patients with atrial fibrillation and acute coronary syndrome, combining a DOAC with a potent P2Y12 inhibitor (prasugrel or ticagrelor) increases bleeding risk without reducing ischemic events compared to a regimen of DOAC plus clopidogrel.
Limitations
- Prematurely terminated after enrollment of 602 of 1,474 patients due to safety concerns.
- Hierarchical win-loss ratio approach means subsequent analyses are exploratory.
- Standalone bleeding complications were secondary endpoints.
- Selection of escalated P2Y12 inhibitor and factor Xa inhibitor was at the discretion of the treating physician.
- All patients underwent peri-interventional loading with aspirin.
- Only 18% of screened patients met the inclusion criteria and agreed to participate.
- Statistical design was modified during the course of the trial.
- Prematurely terminated after enrollment of 602 of an expected 1,474 patients
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Rizas et al. (2026) conducted an RCT in Atrial fibrillation and acute coronary syndrome (n=602). DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) vs. DOAC plus clopidogrel and in-hospital aspirin was evaluated on Hierarchic composite of death, stent thrombosis, myocardial infarction, ischemic stroke, systemic thromboembolism and urgent revascularization (WLR 1.19, 95% CI 0.61-2.32, p=0.610). In patients with atrial fibrillation and acute coronary syndrome, a 1-month regimen of a DOAC plus a potent P2Y12 inhibitor did not reduce ischemic events (WLR 1.19) but increased bleeding.